Premium
Minocycline for Short‐Term Neuroprotection
Author(s) -
Elewa Hazem F.,
Hilali Hend,
Hess David C.,
Machado Livia S.,
Fagan Susan C.
Publication year - 2006
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.26.4.515
Subject(s) - minocycline , neuroprotection , medicine , pharmacology , stroke (engine) , antibiotics , biology , mechanical engineering , microbiology and biotechnology , engineering
Minocycline is a widely used tetracycline antibiotic. For decades, it has been used to treat various gram‐positive and gram‐negative infections. Minocycline was recently shown to have neuroprotective properties in animal models of acute neurologic injury. As a neuroprotective agent, the drug appears more effective than other treatment options. In addition to its high penetration of the blood‐brain barrier, minocycline is a safe compound commonly used to treat chronic infections. Its several mechanisms of action in neuroprotection—antiinflammatory and antiapoptotic effects, and protease inhibition—make it a desirable candidate as therapy for acute neurologic injury, such as ischemic stroke. Minocycline is ready for clinical trials of acute neurologic injury.